Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

virbac (australia) pty ltd - ferric chloride - unknown - ferric chloride mineral-iron active 0.0 - active constituent

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - sodium ferric gluconate complex (unii: cc9149u2qx) (ferric cation - unii:91o4lml611) - ferric cation 12.5 mg in 1 ml - sodium ferric gluconate complex in sucrose injection is indicated for the treatment of iron deficiency anemia in adult patients and in pediatric patients age 6 years and older with chronic kidney disease receiving hemodialysis who are receiving supplemental epoetin therapy. sodium ferric gluconate complex in sucrose injection is contraindicated in patients with known hypersensitivity to sodium ferric gluconate or any of its components. reactions have included anaphylaxis [see warnings and precautions (5.1) ]. risk summary parenteral iron administration may be associated with hypersensitivity reactions [see warnings and precautions (5.1) ], which may have serious consequences, such as fetal bradycardia (see clinical considerations ). advise pregnant women of the potential risk to the fetus. available data from postmarketing reports with sodium ferric gluconate complex in sucrose injection use in pregnancy are insufficient to assess the risk of major birth defects and miscarriage. sodium ferric gluconate comple

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - sodium ferric gluconate complex (unii: cc9149u2qx) (ferric cation - unii:91o4lml611) - ferric cation 12.5 mg in 1 ml - sodium ferric gluconate complex in sucrose injection is indicated for the treatment of iron deficiency anemia in adult patients and in pediatric patients age 6 years and older with chronic kidney disease receiving hemodialysis who are receiving supplemental epoetin therapy. sodium ferric gluconate complex in sucrose injection is contraindicated in patients with known hypersensitivity to sodium ferric gluconate or any of its components. reactions have included anaphylaxis [see warnings and precautions (5.1) ]. risk summary parenteral iron administration may be associated with hypersensitivity reactions [see warnings and precautions (5.1) ], which may have serious consequences, such as fetal bradycardia (see clinical considerations ). advise pregnant women of the potential risk to the fetus. available data from postmarketing reports with sodium ferric gluconate complex in sucrose injection use in pregnancy are insufficient to assess the risk of major birth defects and miscarriage. sodium ferric gluconate comple

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

glenmark pharmaceuticals (malaysia) sdn. bhd. - ferric hydroxide-polymaltose complex -

Kenya - English - Pharmacy and Poisons Board

glenmark pharmaceuticals limited glenmark house, hdo-corporate building, wing – a, - ferric hydroxide polymaltose complex ih - syrup - elemental iron 50mg - antianemic preparations - iron preparations: iron

Kenya - English - Pharmacy and Poisons Board

ferric hydroxide in complex with sucrose… - injection - 20 mg/ml - antianemic preparations - iron preparations: iron

Canada - English - Health Canada

pharmacosmos a/s - iron (iron dextran complex) - solution - 200mg - iron (iron dextran complex) 200mg - swine (pigs)

Canada - English - Health Canada

pharmacosmos a/s - iron (ferric derisomaltose) - solution - 100mg - iron (ferric derisomaltose) 100mg - iron preparations

Ireland - English - HPRA (Health Products Regulatory Authority)

vifor france - iron (iii) - hydroxide sucrose complex - solution for injection/infusion - 20  milligram(s)/millilitre - iron trivalent, oral preparations; saccharated iron oxide

United States - English - NLM (National Library of Medicine)

ropack inc. - ferric pyrophosphate citrate (unii: uby79oco9g) (ferric cation - unii:91o4lml611) - ferric cation 272 mg in 272 mg - triferic is an iron replacement product indicated for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease (hdd-ckd). triferic is not intended for use in patients receiving peritoneal dialysis. triferic has not been studied in patients receiving home hemodialysis. none risk summary there are no data with triferic use in pregnant women to inform a drug-associated risk. no teratogenicity was observed in animal reproduction studies with administration of ferric pyrophosphate citrate to pregnant rats and rabbits during organogenesis at doses 96 and 128 times, respectively, the maximum recommended human dose (mrhd) of 27.2 mg per dialysis [see data]. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%–4% and 15%–20%, respectively. data animal data in a fertility and early embryonic development study in female rats, the maternally toxic ferric pyrophosphate citra